Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmaniaga BhdXKLS:7081 66 EBITDA Margin % is 2.69% as of Jun. 2026, which is 31% below its 10-year median of 3.92. GuruFocus rates XKLS:7081 with a GF Score™ of 66/100 and a GF Value™ of RM1.11 (Fairly Valued). The stock has 6 warning signs investors should review. Among 119 Medical Distribution companies, Pharmaniaga Bhd ranks worse than 62.18% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Pharmaniaga Bhd's EBITDA for the
three
months ended in Jun. 2026 was RM28 Mil. Pharmaniaga Bhd's Revenue for the
three
months ended in Jun. 2026 was RM1,041 Mil. Therefore, Pharmaniaga Bhd's EBITDA margin for the quarter that ended in Jun. 2026 was 2.69%.
Pharmaniaga Bhd (XKLS:7081) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Pharmaniaga Bhd EBITDA Margin % Related Terms
Pharmaniaga Bhd EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Pharmaniaga Bhd's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:7081 vs MCK, COR, CAH: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Pharmaniaga Bhd's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmaniaga Bhd EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Pharmaniaga Bhd's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Pharmaniaga Bhd's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmaniaga Bhd (XKLS:7081) has a EBITDA Margin % of 2.69% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pharmaniaga Bhd and its competitors. This is 31% below median its historical median of 3.92. According to the industry distribution chart, Pharmaniaga Bhd ranks #74 out of 119 companies in the Medical Distribution industry, placing it in the top 62.2%.
Is Pharmaniaga Bhd's EBITDA Margin % too high?
Pharmaniaga Bhd's current EBITDA Margin % of 2.69% is 31% below median its 10-year median of 3.92. The Medical Distribution industry median EBITDA Margin % is 4.28. Pharmaniaga Bhd's value of 2.69% is 37.1% below this industry median. Based on the distribution chart, Pharmaniaga Bhd ranks #74 out of 119 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Pharmaniaga Bhd has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharmaniaga Bhd's EBITDA Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Pharmaniaga Bhd ranks #74 out of 119 companies for EBITDA Margin %. This places Pharmaniaga Bhd in the lower half of its industry. The industry median EBITDA Margin % is 4.28. Pharmaniaga Bhd's value of 2.69% is 37.1% below this benchmark. While the company's 10-year median is 3.92 vs. the industry median of 4.28, Pharmaniaga Bhd has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.28, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmaniaga Bhd's current EBITDA Margin % of 2.69% is 37.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pharmaniaga Bhd and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmaniaga Bhd's current EBITDA Margin % is 2.69%, which is 31% below median its own 10-year median of 3.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaniaga Bhd stock overvalued right now?
Based on GuruFocus' analysis, Pharmaniaga Bhd (XKLS:7081) is currently considered Fairly Valued. The stock's GF Value™ is RM1.11, compared to a current price of RM1.19 — trading 7.2% above its estimated fair value. The current EBITDA Margin % is 2.69%, which is 31% below median its 10-year median of 3.92 and 37.1% below the Medical Distribution industry median of 4.28. Pharmaniaga Bhd's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Pharmaniaga Bhd (XKLS:7081), the current EBITDA Margin % is 2.69% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmaniaga Bhd (XKLS:7081) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmaniaga Bhd stock appears to be overvalued.
The current stock price of RM1.19 is trading 7.2% above its estimated GF Value™ of RM1.11.
GuruFocus considers Pharmaniaga Bhd to be Fairly Valued.
Key valuation signals for XKLS:7081:
EBITDA Margin %: 2.69% (31% below median its 10-year median of 3.92)
GF Value™: RM1.11 vs. price of RM1.19 (7.2% above fair value)
Industry Position: 37.1% below the Medical Distribution median (#74 of 119)
No single metric tells the full story. See the XKLS:7081 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmaniaga Bhd is engaged in the manufacture of pharmaceuticals and medical devices. The company is also involved in logistics and distribution. The group operates in three segments - Logistics and distribution, Manufacturing in Malaysia, and Manufacturing and distribution in Indonesia. Maximum revenue is generated by the logistics and distribution segment in Malaysia. The Logistics and distribution segment is engaged in distribution, trading and wholesaling of pharmaceutical and medical products as well as supply and installation of medical and hospital equipment in Malaysia.
66GF Score
Get the complete analysis for XKLS:7081
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7081 has been successfully added to your 
